Biotechnology company Lycia Therapeutics (LYCA.US), specializing in allergies and autoimmune diseases, will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

智通财经2026/10/23 02:46

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Golden Ten Data APP, Lycia Therapeutics, a biotechnology company focused on the treatment of allergies and autoimmune diseases, has expanded the size of its upcoming initial public offering (IPO) in the United States. According to a statement released by the company on Thursday, Lycia will issue 17.64 million shares at a price of $18 per share, aiming to raise $317.5 million. A previous filing showed that the biotech company had originally planned to issue 14.7 million shares at a price range of $16 to $18 per share.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56